Cambridge Heart, Inc. (CAMH) Trial Results Reinforce Value of MTWA Test to Predict Potentially Fatal Cardiac Events
Cambridge Heart, developer of non-invasive diagnostic tests for cardiac disease, today announced that the results of a 155-patient trial test of the Microvolt T-Wave Alternans™ (MTWA) confirm the technology as a valuable predictor of life-threatening heart rhythms and Sudden Cardiac Death (SCD). MTWA measures the risk of sudden cardiac arrest (SCA), which is determined during a non-invasive treadmill test using Cambridge Heart’s proprietary technologies. The company notes that MTWA test is the only one of its kind that is reimbursed by Medicare under a National Coverage Policy. The study involved 155 patients who first underwent MTWA testing using Cambridge Heart’s…